{"id":"https://openalex.org/W2346862687","doi":"https://doi.org/10.1080/14728214.2016.1184644","title":"Emerging targeted therapies for melanoma","display_name":"Emerging targeted therapies for melanoma","publication_year":2016,"publication_date":"2016-04-02","ids":{"openalex":"https://openalex.org/W2346862687","doi":"https://doi.org/10.1080/14728214.2016.1184644","mag":"2346862687","pmid":"https://pubmed.ncbi.nlm.nih.gov/27148822"},"language":"en","primary_location":{"id":"doi:10.1080/14728214.2016.1184644","doi":"https://doi.org/10.1080/14728214.2016.1184644","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14728214.2016.1184644","pdf_url":null,"source":{"id":"https://openalex.org/S66445379","display_name":"Expert Opinion on Emerging Drugs","issn_l":"1472-8214","issn":["1472-8214","1744-7623"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Emerging Drugs","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025067315","display_name":"Douglas Buckner Johnson","orcid":"https://orcid.org/0000-0002-6390-773X","observed_orcids":["https://orcid.org/0000-0002-6390-773X"]},"institutions":[{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Douglas B. Johnson","raw_affiliation_strings":["a Department of Medicine , Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center , Nashville , TN , USA","Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a Department of Medicine , Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center , Nashville , TN , USA","institution_ids":["https://openalex.org/I4390039299","https://openalex.org/I901861585"]},{"raw_affiliation_string":"Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA","institution_ids":["https://openalex.org/I4390039299","https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035110956","display_name":"Megan Lynn Hames Pollack","orcid":"https://orcid.org/0000-0001-8632-7984","observed_orcids":["https://orcid.org/0000-0001-8632-7984"]},"institutions":[{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Megan H. Pollack","raw_affiliation_strings":["b Department of Pharmacology , Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center , Nashville , TN , USA","Department of Pharmacology, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"b Department of Pharmacology , Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center , Nashville , TN , USA","institution_ids":["https://openalex.org/I4390039299","https://openalex.org/I901861585"]},{"raw_affiliation_string":"Department of Pharmacology, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA","institution_ids":["https://openalex.org/I4390039299","https://openalex.org/I901861585"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075566772","display_name":"Jeffrey Alan Sosman","orcid":"https://orcid.org/0000-0002-0650-9698","observed_orcids":["https://orcid.org/0000-0002-0650-9698"]},"institutions":[{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]},{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey A. Sosman","raw_affiliation_strings":["a Department of Medicine , Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center , Nashville , TN , USA","Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a Department of Medicine , Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center , Nashville , TN , USA","institution_ids":["https://openalex.org/I4390039299","https://openalex.org/I901861585"]},{"raw_affiliation_string":"Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA","institution_ids":["https://openalex.org/I4390039299","https://openalex.org/I901861585"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5025067315"],"corresponding_institution_ids":["https://openalex.org/I4390039299","https://openalex.org/I901861585"],"apc_list":null,"apc_paid":null,"fwci":0.4228,"has_fulltext":false,"cited_by_count":26,"citation_normalized_percentile":{"value":0.37401402,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":98},"biblio":{"volume":"21","issue":"2","first_page":"195","last_page":"207"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.9330000281333923},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7630000114440918},{"id":"https://openalex.org/keywords/braf-inhibitors","display_name":"BRAF inhibitors","score":0.8190000057220459},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.7310000061988831},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.7919999957084656},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.921999990940094},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.800000011920929}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8430807590484619},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6690967082977295},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.6574926972389221},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.45308437943458557},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.4406869113445282},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.4315153956413269},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.42021340131759644},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3935639262199402},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.32591724395751953},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.32158464193344116},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.31503957509994507},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.28860023617744446},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.2826436161994934},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.2742724120616913},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.21582376956939697},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.21171081066131592},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1588834524154663},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.08692175149917603}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/14728214.2016.1184644","doi":"https://doi.org/10.1080/14728214.2016.1184644","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14728214.2016.1184644","pdf_url":null,"source":{"id":"https://openalex.org/S66445379","display_name":"Expert Opinion on Emerging Drugs","issn_l":"1472-8214","issn":["1472-8214","1744-7623"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Emerging Drugs","raw_type":"journal-article"},{"id":"pmid:27148822","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27148822","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on emerging drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":71,"referenced_works":["https://openalex.org/W1464936406","https://openalex.org/W1550536217","https://openalex.org/W1804117510","https://openalex.org/W1917632054","https://openalex.org/W1949194567","https://openalex.org/W1950572133","https://openalex.org/W1965370740","https://openalex.org/W1967884480","https://openalex.org/W1967902354","https://openalex.org/W1971574630","https://openalex.org/W1977889509","https://openalex.org/W1985850253","https://openalex.org/W1988379285","https://openalex.org/W2005354746","https://openalex.org/W2032211985","https://openalex.org/W2035000040","https://openalex.org/W2038434969","https://openalex.org/W2039123767","https://openalex.org/W2053520756","https://openalex.org/W2054913636","https://openalex.org/W2057272791","https://openalex.org/W2061695178","https://openalex.org/W2073083472","https://openalex.org/W2074671154","https://openalex.org/W2077517114","https://openalex.org/W2082167659","https://openalex.org/W2095911832","https://openalex.org/W2096223992","https://openalex.org/W2097914739","https://openalex.org/W2097995306","https://openalex.org/W2098395271","https://openalex.org/W2099648846","https://openalex.org/W2102031533","https://openalex.org/W2103152130","https://openalex.org/W2109274792","https://openalex.org/W2115111964","https://openalex.org/W2115369775","https://openalex.org/W2116386978","https://openalex.org/W2118102300","https://openalex.org/W2121545342","https://openalex.org/W2124427232","https://openalex.org/W2126361538","https://openalex.org/W2128035403","https://openalex.org/W2128327828","https://openalex.org/W2128542677","https://openalex.org/W2133075384","https://openalex.org/W2134471382","https://openalex.org/W2136474966","https://openalex.org/W2137723371","https://openalex.org/W2141830999","https://openalex.org/W2143923888","https://openalex.org/W2144096834","https://openalex.org/W2146772089","https://openalex.org/W2147474070","https://openalex.org/W2149793889","https://openalex.org/W2151261375","https://openalex.org/W2152897456","https://openalex.org/W2154841567","https://openalex.org/W2155461614","https://openalex.org/W2156078931","https://openalex.org/W2156266404","https://openalex.org/W2160766792","https://openalex.org/W2163188200","https://openalex.org/W2166262263","https://openalex.org/W2166662937","https://openalex.org/W2170552969","https://openalex.org/W2176310149","https://openalex.org/W2201379305","https://openalex.org/W2248712381","https://openalex.org/W2415255830","https://openalex.org/W2416204731"],"related_works":["https://openalex.org/W4251439806","https://openalex.org/W1994974331","https://openalex.org/W7214752963","https://openalex.org/W2017844495","https://openalex.org/W2069278232","https://openalex.org/W4393167333","https://openalex.org/W2125038885","https://openalex.org/W1916356108","https://openalex.org/W2002755395","https://openalex.org/W4381149479"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Melanoma":[1],"is":[2],"an":[3],"aggressive":[4],"cutaneous":[5],"malignancy":[6],"associated":[7],"with":[8,38,91],"poor":[9],"response":[10],"to":[11,28,146,165],"traditional":[12],"therapies.":[13,55,84,99],"Recent":[14],"regulatory":[15],"approval":[16],"for":[17,36,53,69],"immune":[18,81,166],"checkpoint":[19],"inhibitors":[20],"and":[21,58,82,124],"agents":[22,88,104],"targeting":[23],"mutated":[24],"BRAF":[25],"has":[26],"led":[27],"a":[29,92,143,158],"tremendous":[30],"expansion":[31],"of":[32,62,160],"effective":[33,67,149],"treatment":[34,162],"options":[35],"patients":[37],"advanced":[39],"melanoma.":[40],"Unfortunately,":[41],"primary":[42],"or":[43],"acquired":[44],"resistance":[45],"develops":[46],"in":[47,89,135,163],"most":[48],"patients,":[49],"highlighting":[50],"the":[51,132,139],"need":[52,145],"additional":[54],"Numerous":[56],"genetic":[57],"other":[59,115],"molecular":[60],"features":[61],"this":[63],"disease":[64],"may":[65],"provide":[66],"targets":[68],"therapy":[70,153,167],"development.":[71],"AREAS":[72],"COVERED:":[73],"This":[74],"article":[75],"reviews":[76],"available":[77],"melanoma":[78,136,161],"treatments,":[79],"including":[80],"molecularly-targeted":[83],"We":[85],"then":[86],"discuss":[87,103],"development,":[90],"focus":[93],"on":[94],"targeted":[95],"(rather":[96],"than":[97],"immune)":[98],"In":[100],"particular,":[101],"we":[102],"that":[105],"block":[106],"mitogen-activated":[107],"protein":[108],"kinase":[109],"(MAPK)":[110],"signaling,":[111],"as":[112,114,119],"well":[113],"emerging":[116],"approaches":[117,154],"such":[118],"antibody-drug":[120],"conjugates,":[121],"cell-cycle":[122],"targeting,":[123],"novel":[125],"genetically-informed":[126],"clinical":[127],"trials.":[128],"EXPERT":[129],"OPINION:":[130],"Despite":[131],"incredible":[133],"advances":[134],"therapeutics":[137],"over":[138],"last":[140],"several":[141],"years,":[142],"clear":[144],"develop":[147],"more":[148],"therapies":[150],"remains.":[151],"Molecularly-targeted":[152],"will":[155],"likely":[156],"remain":[157],"cornerstone":[159],"parallel":[164],"strategies.":[168]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}